Patents Assigned to Washington University in St. Louis
-
Patent number: 11858956Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.Type: GrantFiled: December 17, 2021Date of Patent: January 2, 2024Assignees: Southern Research Institute, Oregon Health & Science University, Washington University in St. Louis, Board of Regents, The University of Texas SystemInventors: Omar Moukha-Chafiq, Ashish Kumar Pathak, Shuklendu D. Karyakarte, Larry D. Bratton, Corinne E. Augelli-Szafran, Michael Diamond, Pei Yong Shi, Alec Jay Hirsch, Jessica Lee Smith, Daniel Streblow, Nicole Haese, Baoling Ying
-
Patent number: 11717519Abstract: Methods of using small molecule inhibitors of fatty acid oxidation (FAO) as antimicrobials against intracellular Mycobacteria are disclosed. FAO inhibitors including etomoxir, trimetazidine, oxfenicine perhexeline and/or can be used alone, or in combination with known as antimycobacterial agents against intracellular Mycobacteria.Type: GrantFiled: March 15, 2019Date of Patent: August 8, 2023Assignees: Washington University in St. Louis, New York UniversityInventors: Jennifer A. Philips, Kathryn Moore, Pallavi Chandra, Mireille Ouimet
-
Patent number: 11597917Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.Type: GrantFiled: June 6, 2018Date of Patent: March 7, 2023Assignees: The Medical College of Wisconsin, Inc., University Health Network, Washington University in St. LouisInventors: Jeffrey A. Medin, John F. Dipersio, Murtaza S. Nagree
-
Patent number: 11154201Abstract: Provided are implantable biomedical devices and related methods for interfacing with a target tissue. The devices comprise a substrate, an electronic device supported by the substrate and a freely positionable injectable needle electronically connected to the electronic device by a deformable interconnect, where the injectable needle has one or more optical sources provided on a distal tip end. The injectable needle may further comprise a photodetector.Type: GrantFiled: March 31, 2017Date of Patent: October 26, 2021Assignees: The Board of Trustees of the University of Illinois, Washington University in St. LouisInventors: John A. Rogers, Gunchul Shin, Anthony R. Banks, Michael Bruchas, Robert Gereau
-
Patent number: 11129816Abstract: Described is a composition that includes: (i) a drug against tuberculosis inhibiting the cytochrome b subunit of the bc1 complex, said cytochrome b subunit being encoded by the gene qcrB, in Mycobacterium tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 5, 2018Date of Patent: September 28, 2021Assignees: Quretech Bio AB, Washington University in St. LouisInventors: Christina Leigh Stallings, Gregory Alexander Harrison, Fredrik Almqvist, Souvik Sarkar
-
Patent number: 11085933Abstract: The present disclosure is generally related to neurofibromatosis type 1. More particularly, disclosed herein are methods for detecting behavioral disorders, methods for detecting cognitive impairment, and methods for detecting brain neurofibromin-dependent dopaminergic signaling associated with neurofibromatosis type 1.Type: GrantFiled: October 4, 2019Date of Patent: August 10, 2021Assignee: Washington University in St. LouisInventors: David H. Gutmann, Corina Anastasaki
-
Patent number: 10813941Abstract: A pharmaceutical composition includes a small molecule and a pharmaceutically acceptable excipient. The small molecule interacts with a deoxyxylulose phosphate reductoisomerase (Dxr). A method for treating or preventing a microbial infection in a subject in need thereof includes administering the pharmaceutical composition. A method for inhibiting the growth of a eukaryotic pathogen includes contacting the eukaryotic pathogen with an effective amount of the pharmaceutical composition.Type: GrantFiled: January 23, 2017Date of Patent: October 27, 2020Assignees: The George Washington University, A Congressionally Chartered Not-For-Profit Corporation, Washington University in St. LouisInventors: Cynthia Dowd, Audrey Odom, Rachel Edwards, Robert Brothers
-
Publication number: 20200140469Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions, and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum or related Plasmodium parasite species and Mycobacterium tuberculosis or related Mycobacterium bacteria species. The compounds are ?,?-unsaturated analogs of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum.Type: ApplicationFiled: June 27, 2018Publication date: May 7, 2020Applicants: The George Washington University, Washington University in St. Louis, George Mason University, Saint Louis UniversityInventors: Cynthia Dowd, Xu WANG, Robert Carl BROTHERS, Audrey Ragan Odom JOHN, Rachel EDWARDS, Marvin MEYERS, Stacy ARNETT, Robin COUCH, Kenneth HEIDEL
-
Patent number: 10241110Abstract: Plasmonic nanotransducers, methods of preparing plasmonic nanotransducers, and methods for label-free detection of target molecules are disclosed. The plasmonic nanotransducers include hollow nanostructure cores and artificial antibodies. The plasmonic nanotransducers are exposed to a biological sample that can contain the specific target molecules. The plasmonic nanotransducers can be analyzed with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the target molecule in the sample.Type: GrantFiled: October 17, 2014Date of Patent: March 26, 2019Assignee: Washington University in St. LouisInventors: Srikanth Singamaneni, Limei Tian, Keng-Ku Liu, Abdennour Abbas, Jeremiah J. Morrissey, Evan D. Kharasch
-
Patent number: 9980660Abstract: A non-transitory computer readable medium stores instructions that, when executed by at least one processor, cause the at least one processor to perform a method that includes computing a transfer matrix representing a relative influence that each respective electrode location for measuring electrical potentials on a patient's body has on an estimation of electrical potentials for locations on a surface of interest prior to the measuring of electrical potentials at the respective electrode locations and receiving electrical potential measurements measured via a plurality of electrodes at respective electrode locations on the patient's body. The method also includes computing the estimation of electrical potentials for the locations on the surface of interest based at least in part on the received electrical potential measurements and the computed transfer matrix and generating image data representing the estimation of electrical potentials.Type: GrantFiled: January 7, 2016Date of Patent: May 29, 2018Assignee: Washington University in St. LouisInventors: Yoram Rudy, Yong Wang
-
Patent number: 9410949Abstract: Natural and/or synthetic antibodies for specific proteins are adhered to nanoparticles. The nanoparticles are adhered to a substrate and the substrate is exposed to a sample that may contain the specific proteins. The substrates are then tested with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the specific protein in the sample.Type: GrantFiled: December 2, 2011Date of Patent: August 9, 2016Assignee: Washington University in St. LouisInventors: Srikanth Singamaneni, Evan Kharasch, Jeremiah J. Morrissey, Chang Hee Lee
-
Patent number: 9259166Abstract: A computer-implemented method for electrocardiographic imaging (ECGI) is provided. The method includes computing a transfer matrix, measuring a plurality of electrical potentials, and computing an estimation of electrical potentials on a surface of interest based at least in part on the measured potentials and the computed transfer matrix. The transfer matrix computing step is performed prior to the measuring step.Type: GrantFiled: August 10, 2009Date of Patent: February 16, 2016Assignee: Washington University in St. LouisInventors: Yoram Rudy, Yong Wang
-
Patent number: 8889378Abstract: The invention provides methods for identifying a compound that inhibits cytochrome c synthesis. This invention further provides a method for the high throughput screening of compounds that inhibit cytochrome c synthesis.Type: GrantFiled: July 7, 2010Date of Patent: November 18, 2014Assignee: Washington University in St. LouisInventor: Robert Kranz
-
Publication number: 20140234841Abstract: In one aspect, the disclosure provides isolated nucleic acids, polypeptides, primers, and probes for the detection of mutations in a nucleic acid sequence for a DICER1 polypeptide.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicants: Children's Hospital and Clinics of Minnesota, The Washington University in St. LouisInventors: Ashley D. Hill, Paul Goodfellow, John R. Priest, Yoav Messinger
-
Patent number: 8597893Abstract: A novel function phospholipase A2, referred to herein as calcium-independent phospholipase A2? (iPLA2?) having SEQ ID NO: 1 and SEQ ID NO: 2, and nucleic acid sequences (SEQ ID NO: 3 and SEQ ID NO: 4) encoding and expressing iPLA2? is disclosed. This novel enzyme has been isolated and characterized and is involved in the catalysis and hydrolysis of lipids cycling in a living cell biosystem. In an embodiment, the iPLA2? polypeptide is encoded and expressed by an isolated nucleic acid molecule comprising a set of iPLA2? polynucleotides. In one aspect, an isolated and characterized gene comprises a polynucleotide having a sequence shown in SEQ ID NO: 3 and SEQ ID NO: 4.Type: GrantFiled: March 1, 2010Date of Patent: December 3, 2013Assignee: Washington University In St. LouisInventors: Richard W. Gross, Christopher M. Jenkins
-
Patent number: 8591562Abstract: A device for cooling the central nervous system (e.g., the brain) is disclosed that is specifically designed to provide cooling of an injured central nervous system for neuroprotective, antiepileptogenic, and/or antiepileptic treatments. In one embodiment, a portion of the cooling device is placed in a recess formed by removal of a portion of a patient's skull. An embedded heat-collecting portion of the cooling device is formed to fit in the location of the formed recess and a thermally conductive material of the heat-collecting portion is placed adjacent the dura mater to provide the desired degree of cooling. A heat-dissipating external plate is in thermal contact with the internal plate, and can be selectively sized according to a specific purpose.Type: GrantFiled: December 2, 2009Date of Patent: November 26, 2013Assignees: University of Washington, Regents of the University of Minnesota, Washington University in St. LouisInventors: Raimondo D'Ambrosio, Matthew Smyth, Steven Mark Rothman, John W. Miller, Jason Fender
-
Patent number: 8580517Abstract: G protein biosensors comprising mammalian G protein subunits fused to fluorescent proteins emitting a FRET signal expressed in living intact functional cells. The intensity of the FRET signal is strongly responsive to the activation state of the biosensors. The biosensors respond reproducibly to agonist and antagonist drug molecules specific for G protein coupled receptors. The biosensors have utility in identifying and classifying candidate therapeutic drugs as to their therapeutic value.Type: GrantFiled: February 4, 2004Date of Patent: November 12, 2013Assignee: Washington University in St. LouisInventors: Narasimhan Gautam, Inaki Azpiazu
-
Publication number: 20120307037Abstract: A microscope assembly includes an illumination source coupled to an optical assembly by a coupler. The optical assembly includes an objective with optics that move along an optic axis. The illumination source generates a light blade that illuminates a portion of a sample at an illumination plane. The light blade induces a fluorescent emission from the sample that is projected through the objective optics to a detector. The focal plane of the objective optics is fixed with respect to the illumination source by the coupler so that the illumination plane is coincident with the focal plane as the objective optics move along the optic axis. The objective and illumination may be rapidly scanned along the optic axis to provide rapid three-dimensional imaging while the objective and illumination may also be rapidly scanned along the optic axis to provide rapid three-dimensional imaging.Type: ApplicationFiled: August 1, 2012Publication date: December 6, 2012Applicant: Washington University in St. LouisInventors: Timothy E. Holy, Terrence F. Holekamp
-
Patent number: 8318133Abstract: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing compounds as contrast agents. Novel macrocyclic cyanine and indocyanine bioconjugates that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These compounds are especially useful for endoscopic, localized photoacoustic, and sonofluorescence imaging, detection and therapy of tumors and other abnormalities.Type: GrantFiled: November 2, 2010Date of Patent: November 27, 2012Assignee: Washington University in St. LouisInventors: Samuel Achilefu, Yunpeng Ye
-
Publication number: 20120268731Abstract: A particle detection system is provided. The particle detection system includes at least one tapered optical fiber, a light source configured to transmit light through the at least one tapered optical fiber, a photodetector configured to measure a characteristic of the light being transmitted through the at least one optical fiber, and a computing device coupled to the photodetector and configured to determine whether a nanoparticle is present within an evanescent field of the at least one tapered optical fiber based on the measured light characteristic.Type: ApplicationFiled: April 30, 2012Publication date: October 25, 2012Applicant: Washington University in St. LouisInventors: Jiangang Zhu, Sahin Kaya Ozdemir, Lan Yang